Cubist Pharmaceutical CEO Michael Bonney talks to CNBC's Bertha Coombs about his company's big bet on antibiotics to treat superbugs, which recently drove the firm to acquire two smaller rivals. He leaves the door open to future deals.

LEXINGTON, Mass.-- Cubist Pharmaceuticals Inc. said Thursday that its net income rose 66 percent in the third quarter on greater sales of its antibiotic Cubicin and other products, and lower tax costs. The company said its net income grew to $40.3 million, or 55 cents per share, in the three months through Sept. 30, from $24.2 million, or 33 cents per share, a year ago.